| Autor: |
Gill, C.M. Aktaş, E. Alfouzan, W. Bourassa, L. Brink, A. Burnham, C.-A.D. Canton, R. Carmeli, Y. Falcone, M. Kiffer, C. Marchese, A. Martinez, O. Pournaras, S. Seifert, H. Thabit, A.K. Villegas, M.V. Westblade, L.F. Nicolau, D.P. Wille, J. Rezende, T.T.F. Cekin, Z. Malkocoglu, G. Gijón, D. Tarakmeh, L.A. Chu, C.Y. Opperman, C.J. Tootla, H.D. Moodley, C. Coetzee, J. Vourli, S. Dimopoulos, G. Attallah, D.M. Tiseo, G. Leonildi, A. Giordano, C. Barnini, S. Menichetti, F. Di Pilato, V. Codda, G. Vena, A. Giacobbe, D.R. Satlin, M. Cardona, A. Curtis, L. Fang, F. Thomson, G. Thomson, K. the ERACE-PA Global Study Group |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
